๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Inhibition of mouse mammary carcinoma development with doxorubicin in liposomes

โœ Scribed by Jan Vaage; Peter Working; Paul Uster

Publisher
John Wiley and Sons
Year
1998
Tongue
French
Weight
35 KB
Volume
75
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

โœฆ Synopsis

Monthly treatments with intravenous doxorubicin encapsulated in long circulating, sterically stabilized liposomes delayed the appearance of primary mammary carcinomas and reduced the final incidence from 49 in 50 untreated mice to 46 in 87 treated mice. No toxic side effects of the treatments were observed.

๐Ÿ“œ SIMILAR VOLUMES

Therapy of primary and metastatic mouse
Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long circulating liposomes
โœ Jan Vaage; Eric Mayhew; Dan Lasic; Frank Martin ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 639 KB

The purpose of our study was to compare the therapeutic effects of doxorubicin in 3 different formulations: (I) in PBS, (2) in conventional liposomes composed of egg phosphatidylglycerol/ egg phosphatidylcholine/cholesterol/dl-a tocopherol, and (3) in sterically stabilized, long-circulating "Stealth

Growth inhibition of human mammary carci
Growth inhibition of human mammary carcinoma by liposomal hexadecylphosphocholine: Participation of activated macrophages in the antitumor mechanism
โœ Ines Eue ๐Ÿ“‚ Article ๐Ÿ“… 2001 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 303 KB

This study was undertaken to investigate the antitumor effect of liposomal hexadecylphosphocholine (L-HPC), a synthetic phospholipid encapsulated into multilamellar vesicles (MLV). The effect of these liposomes was tested in an orthotopic nude mouse model using the human mammary carcinomas MDA-MB 43